A new partnership to develop IRAK-4 inhibitors

Ligand Pharmaceuticals (LGND) and TG Therapeutics (TGTX) team up to develop and commercialize Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. The program is currently in the preclinical stage for certain cancers and autoimmune diseases.

Under the terms of the agreement, Ligand will receive 125,000 shares of TGTX common stock (value ~$1M) and is eligible to receive $207M in potential milestone payments. Upon regulatory clearance, it will earn tiered royalties of 6 - 9.5% on net sales of licensed products containing patented IRAK-4 inhibitors. The specific royalty scheme is: 6% of annual sales up to $1B and 9.5% of sales above $1B. The royalty rate for licensed products not covered by LGND's issued patents will be 4.5%.

IRAK-4 is a serine/threonine protein kinase that is an important downstream signaling component of the IL-1 receptor and multiple toll-like receptors. It has a key role in innate immunity and inflammation.

Ligand acquired the rights to the technology via its acquisition of Pharmacopeia in 2008.

From other sites
Comments (1)
  • 12100131
    , contributor
    Comments (20) | Send Message
    As it did with the positive Phase I news yesterday, I expect LGND will be down again today with this new positive development- load up while you can- the shots on goal keeps increasing!
    24 Jun 2014, 09:04 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs